Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. The Influence of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation.Journal of clinical laboratory analysis · 2016
   Article
2. Diagnosis and Management of Acute Intracerebral Hemorrhage.Emergency medicine clinics of North America · 2016
   Review
3. Emergency reversal of anticoagulation: novel agents.Current neurology and neuroscience reports · 2014
   Review
4. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.BioMed research international · 2014
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as